Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Approvals & launches

Novartis wins US label for Cosentyx in polymyalgia rheumatica

The FDA clearance gives Novartis a new US indication for the 150 mg dose, though the company has not yet disclosed pricing, launch timing or trial data.

17 Nov 2026 · Novartis Pharma AG · Company news

Novartis has secured US regulatory clearance for a new use of Cosentyx (secukinumab), adding polymyalgia rheumatica (PMR) to the products' American label. The company announced the decision on 17 November 2026. The approval covers the 150 mg dose in adult patients.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Approvals & launchesAll →